Anti-CD90 / Thy1 antibody [EPR3133] (ab133350) is a rabbit monoclonal antibody that is used to detect CD90 / Thy1 in Western Blot, IHC-P, ICC/IF. Suitable for Human samples.
- Specificity confirmed with CD90 / Thy1 knockout cell line validation
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
IHC-P | ICC/IF | IP | Flow Cyt | WB | |
---|---|---|---|---|---|
Human | Tested | Tested | Not recommended | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/50 | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/50 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 - 1/5000 | Notes Observed molecular weight may vary depending on the glycosylation level of the target. |
Select an associated product type
May play a role in cell-cell or cell-ligand interactions during synaptogenesis and other events in the brain.
CD90, Thy-1 membrane glycoprotein, CDw90, Thy-1 antigen, THY1
Anti-CD90 / Thy1 antibody [EPR3133] (ab133350) is a rabbit monoclonal antibody that is used to detect CD90 / Thy1 in Western Blot, IHC-P, ICC/IF. Suitable for Human samples.
- Specificity confirmed with CD90 / Thy1 knockout cell line validation
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
CD90 also known as Thy1 is a glycoprotein with a molecular mass of approximately 25-37 kDa. It is highly conserved across species and found on the surface of various cell types including fibroblasts neurons and endothelial cells. CD90 is expressed in these cells in tissues such as the brain thymus and lungs. Researchers use anti-CD90 antibodies for detection often in combination with CD90 FITC in immunofluorescence assays. CD90 serves as a useful cell marker particularly in identifying mesenchymal stem cells (MSCs).
CD90 plays a role in cell-cell and cell-matrix interactions contributing to cellular adhesion migration and signal transduction. It functions as part of a complex involving integrins which mediate its interaction with the extracellular matrix. This protein also influences T-cell activation reflecting its importance in immune response regulation. Its presence aids in modulating response to injury and promoting tissue repair due to its association with stem and progenitor cells.
CD90 engagement affects focal adhesion and MAPK signaling pathways. It interacts with integrins like αvΒ3 and α5Β1 influencing cell movement and proliferation processes. CD90 involvement in these pathways allows it to regulate responses important for cell survival and communication within various tissues. These interactions highlight the protein's role in maintaining cellular homeostasis and regulating physiological processes.
CD90 has associations with fibrosis and cancer. In fibrotic conditions CD90 expression affects fibroblast activity influencing tissue scarring in organs such as the liver and lungs. In cancer CD90 modifies tumor progression and metastasis by impacting cell adhesion and migration with connections to proteins like TGF-beta which further drive these processes. Understanding CD90 in disease contexts facilitates the development of therapeutic strategies aimed at modulating its activity.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
CD90 / Thy1 Western blot staining using rabbit Anti-CD90 / Thy1 antibody
The molecular weight observed is consistent with what has been described in the literature (PMID: 24116172 and PMID: 30177788).
Blocking Buffer and concentration: 5% NFDM/TBST
All lanes: Western blot - Anti-CD90 / Thy1 antibody [EPR3133] (ab133350) at 1/1000 dilution
Lane 1: Human glioma lysate at 15 µg
Lane 2: Human brain lysate at 15 µg
All lanes: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 17 kDa
Observed band size: 25-35 kDa
CD90 / Thy1 Immunocytochemistry/ Immunofluorescence staining using rabbit Anti-CD90 / Thy1 antibody
Immunocytochemistry analysis of Jurkat (Human T cell leukemia T lymphocyte) cells labeling CD90 / Thy1 with Purified ab133350 at 1:50 dilution (2.44 μg/ml). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1:200 (2.5 μg/ml). Goat anti rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) was used as the secondary antibody at 1:1000 (2 μg/ml) dilution. DAPI (blue) was used as nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.
CD90 / Thy1 Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) staining using rabbit Anti-CD90 / Thy1 antibody
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue sections labeling CD90 / Thy1 with Purified ab133350 at 1:4000 dilution (0.03 µg/ml). Perform heat mediated antigen retrieval using Antigen Retrieval Buffer (100X Tris-EDTA Buffer, pH 9.0) ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
Anti-THY1 antibody [EPR3133] (ab133350) staining at 1/2000 dilution, shown in green; Mouse anti-Alpha Tubulin [DM1A] (Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab133350 was shown to bind specifically to THY1. A band was observed at 25-37 kDa in wild-type U-2 OS cell lysates with no signal observed at this size in THY1 knockout cell line Human THY1 (CD90) knockout U-2 OS cell line ab262490 (knockout cell lysate Human THY1 (CD90) knockout U-2 OS cell lysate ab263925). To generate this image, wild-type and THY1 knockout U-2 OS cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
All lanes: Western blot - Anti-CD90 / Thy1 antibody [EPR3133] (ab133350) at 1/2000 dilution
Lanes 1 - 5: Western blot at 20 µg
Lane 2: Western blot - Human THY1 (CD90) knockout U-2 OS cell lysate (Human THY1 (CD90) knockout U-2 OS cell lysate ab263925)
Lane 2: Western blot - Human THY1 (CD90) knockout U-2 OS cell line (Human THY1 (CD90) knockout U-2 OS cell line ab262490)
All lanes: Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Performed under reducing conditions.
Predicted band size: 17 kDa
Image collected and cropped by CiteAb under a CC-BY license from the publication
CD90 / Thy1 western blot using anti-CD90 / Thy1 antibody [EPR3133] ab133350. Publication image and figure legend from Fu, B., Meng, W., et al., 2016, Sci Rep, PubMed 27585821.
ab133350 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab133350 please see the product overview.
GRAMD1A promotes the self-renewal of HCC stem cell and the resistance to chemotherapy.(a) GSEA analysis of the correlation between GRAMD1A levels and tumor recurrence and HCC stem cells gene signature, data set was downloaded from TCGA data set. (b) Hepatosphere formation assay for the effect of GRAMD1A overexpression on self-renewal of HCC stem cells in Huh-7 and HepG2 cells. Representative micrographs (left); quantification of hepatosphere number (right). (c) SP analysis demonstrated the role of GRAMD1A in self-renewal of HCC stem cells by GRAMD1A overexpression. (d) Western blot assay of the expression of HCC stem cells markers CD130 and CD90 by overexpressing or downregulating GRAMD1A in HepG2. (e) Cell viability assay demonstrated the role of GRAMD1A in resistance to Doxorubicin by GRAMD1A overexpression. (f) TUNEL assay for the effect of GRAMD1A overexpression on resistance to Doxorubicin. Representative micrographs (left); quantification of TUNEL positive cell number (right). DAPI was used to stain nucleus. (g) Western blot assay for caspase 3 activity, PARP cleavage and the BCL-XL levels after GRAMD1A overexpression in Huh-7 and HepG2. Data are expressed as mean ± SEM. *p < 0.05.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com